Anna Pasetto
- Director of ACT, Associate Professor; PhD
I joined the Oslo University Hospital in 2022 as Director of the Center for Advanced Cell Therapy (ACT) and also Associate Professor at the University of Oslo. Since 2018, I worked at the Karolinska Institutet as Assistant Professor and Managing Director of the pre-GMP facility in the Department of Laboratory Medicine, where I am still affiliated to this day as research specialist.
I received my Master Degree in Molecular Biotechnology in 2007 from Alma Mater Studiorum Bologna University, Italy. I then moved to the Karolinska Institutet where I received my PhD in 2012. I joined the laboratory of Dr. Steven Rosenberg as post-doctoral fellow at the National Cancer Institute, NIH in 2013 and my research was focused on the isolation of TCR genes from mutation-reactive tumor infiltrating lymphocytes in metastatic solid cancers.
My professional goal is to facilitate and support the development of new immunotherapies against cancer.
Publications 2025
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity
HLA, 105 (1), e70011
DOI 10.1111/tan.70011, PubMed 39807702
Publications 2024
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
NPJ Precis Oncol, 8 (1), 26
DOI 10.1038/s41698-024-00506-z, PubMed 38302615
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design
Int J Mol Sci, 25 (22)
DOI 10.3390/ijms252212201, PubMed 39596267
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Mol Ther, 32 (2), 540-555
DOI 10.1016/j.ymthe.2024.01.007, PubMed 38213030
Publications 2023
Editorial: Personalized immunotherapy for cancer
Front Oncol, 13, 1171907
DOI 10.3389/fonc.2023.1171907, PubMed 36959783
Publications 2022
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
Gut, 72 (6), 1186-1195
DOI 10.1136/gutjnl-2022-327216, PubMed 35977815
Cancer genes disfavoring T cell immunity identified via integrated systems approach
Cell Rep, 40 (5), 111153
DOI 10.1016/j.celrep.2022.111153, PubMed 35926468
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Int J Mol Sci, 23 (15)
DOI 10.3390/ijms23158590, PubMed 35955721
T-Cell Repertoire Characterization
Methods Mol Biol, 2574, 209-219
DOI 10.1007/978-1-0716-2712-9_9, PubMed 36087203
Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products
Front Immunol, 13, 896242
DOI 10.3389/fimmu.2022.896242, PubMed 35784320
Publications 2021
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
J Infect Dis, 223 (1), 128-138
DOI 10.1093/infdis/jiaa036, PubMed 31994701
Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy
Cancers (Basel), 13 (17)
DOI 10.3390/cancers13174334, PubMed 34503144
Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells
J Immunother, 44 (1), 1-8
DOI 10.1097/CJI.0000000000000342, PubMed 33086340
Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
Front Immunol, 12, 689091
DOI 10.3389/fimmu.2021.689091, PubMed 34163487
Publications 2020
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies
Cells, 9 (6)
DOI 10.3390/cells9061471, PubMed 32560123
Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors
Cancers (Basel), 12 (10)
DOI 10.3390/cancers12102818, PubMed 33007884
Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation
Front Immunol, 11, 552
DOI 10.3389/fimmu.2020.00552, PubMed 32292409
Publications 2019
Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity
Sci Immunol, 4 (31)
DOI 10.1126/sciimmunol.aao4310, PubMed 30635355
Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients
Nat Commun, 10 (1), 449
DOI 10.1038/s41467-019-08304-z, PubMed 30683863
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
J Clin Invest, 129 (11), 4992-5004
DOI 10.1172/JCI127967, PubMed 31609250
Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
Cancer Immunol Res, 7 (4), 534-543
DOI 10.1158/2326-6066.CIR-18-0686, PubMed 30709841
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
J Clin Invest, 129 (3), 1109-1114
DOI 10.1172/JCI123791, PubMed 30714987
Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers
Cancer Discov, 9 (8), 1022-1035
DOI 10.1158/2159-8290.CD-18-1494, PubMed 31164343
Editorial: HBV-the naked truth?
Aliment Pharmacol Ther, 50 (8), 963-964
DOI 10.1111/apt.15428, PubMed 31591767
Publications 2018
T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
Clin Cancer Res, 24 (22), 5562-5573
DOI 10.1158/1078-0432.CCR-18-0573, PubMed 29853601
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
JCI Insight, 3 (19)
DOI 10.1172/jci.insight.122467, PubMed 30282837
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nat Med, 24 (6), 724-730
DOI 10.1038/s41591-018-0040-8, PubMed 29867227
Publications 2017
Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties
J Virol, 91 (9)
DOI 10.1128/JVI.00010-17, PubMed 28228595
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Science, 356 (6334), 200-205
DOI 10.1126/science.aak9510, PubMed 28408606
Publications 2016
A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
Clin Cancer Res, 23 (2), 351-362
DOI 10.1158/1078-0432.CCR-16-0906, PubMed 28093487
Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System
Mol Ther, 24 (6), 1078-1089
DOI 10.1038/mt.2016.51, PubMed 26945006
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Nat Med, 22 (4), 433-8
DOI 10.1038/nm.4051, PubMed 26901407
Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
Clin Cancer Res, 23 (10), 2491-2505
DOI 10.1158/1078-0432.CCR-16-2680, PubMed 27827318
Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor
Cancer Immunol Res, 4 (9), 734-43
DOI 10.1158/2326-6066.CIR-16-0001, PubMed 27354337
Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
Cancer Immunol Res, 4 (8), 669-78
DOI 10.1158/2326-6066.CIR-15-0215, PubMed 27312342
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
N Engl J Med, 375 (23), 2255-2262
DOI 10.1056/NEJMoa1609279, PubMed 27959684
Publications 2013
A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice
J Immunol, 190 (3), 1113-24
DOI 10.4049/jimmunol.1201497, PubMed 23284053
The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon
PLoS One, 8 (6), e65964
DOI 10.1371/journal.pone.0065964, PubMed 23785460
Functional attributes of responding T cells in HCV infection: the recent advances in engineering functional antiviral T cells
Arch Immunol Ther Exp (Warsz), 62 (1), 23-30
DOI 10.1007/s00005-013-0248-8, PubMed 23955531
Publications 2012
TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity
J Immunol, 189 (9), 4510-9
DOI 10.4049/jimmunol.1201613, PubMed 23024278
Publications 2011
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
J Gen Virol, 93 (Pt 2), 247-258
DOI 10.1099/vir.0.037903-0, PubMed 22071510